Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CCR5 | P51681 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5448769 | 0.87 | SLC6A2 (0.53) | MEN1KMT2ACCR5GRIN2BSLC6A2 | |
| SCHEMBL6006925 | 0.86 | LMNA (0.49) | MEN1KMT2AKDM1AALDH1A1GRIN2B | |
| SCHEMBL6009357 | 0.83 | TMEM97 (0.47) | MEN1KMT2AGRIN2BSLC6A2SLC6A3 | |
| SCHEMBL6007229 | 0.82 | KDM4E (0.56) | MEN1KMT2ACCR5GRIN2BSLC6A2 | |
| SCHEMBL4632909 | 0.80 | MEN1 (0.65) | MEN1KMT2AKDM1AALDH1A1GRIN2B | |
| SCHEMBL5754883 | 0.79 | MEN1 (0.51) | MEN1KMT2ACCR5KDM1ACYP19A1 | |
| SCHEMBL6008053 | 0.77 | SLC6A2 (0.54) | MEN1KMT2ACCR5GRIN2BSLC6A2 | |
| SCHEMBL6007222 | 0.76 | ALDH1A1 (0.56) | MEN1KMT2ACCR5ALDH1A1GRIN2B | |
| SCHEMBL6008682 | 0.75 | OPRM1 (0.46) | CCR5GRIN2BSLC6A2SLC6A3CCR3 | |
| SCHEMBL5754882 | 0.74 | MEN1 (0.57) | MEN1KMT2ACCR5KDM1AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078537-B2 | Phenylalkyl diamine and amide analogs | SK CORPORATION (KR) | 2006-07-18 | — | — | US | claimed |
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2003-06-05 | — | — | US | claimed |
| US-7078537-B2 | Phenylalkyl diamine and amide analogs | SK CORPORATION (KR) | 2006-07-18 | — | — | US | disclosed |
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SIGMAR1, TAAR1, OPRL1 | MEN1 4634/4885KMT2A 1375/4885CCR5 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.